Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cholesteryl esters and high protein-to-lipid ratios distinguish non-vesicular extracellular particles from extracellular vesicles.

Cell communication and signaling : CCS·2026

Same author

A Novel Bilateral Upper Limb Training Method for Stroke Rehabilitation.

IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society·2025

Same author

Diabetes-preventive molecular mechanisms of breast versus formula feeding: new insights into the impact of milk on stem cell Wnt signaling.

Frontiers in nutrition·2025

Same author

Therapeutic and pharmacological applications of extracellular vesicles and lipoproteins.

British journal of pharmacology·2024

Same author

Risk of Fat Mass- and Obesity-Associated Gene-Dependent Obesogenic Programming by Formula Feeding Compared to Breastfeeding.

Nutrients·2024

Same author

Circulating perturbation of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) is associated to cardiac remodeling and NLRP3 inflammasome in cardiovascular patients with insulin resistance risk.

Experimental and molecular pathology·2024

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

The Danubian Biobank project.

Gerd Schmitz¹, Charalampos Aslanidis, Gerhard Liebisch

¹Institute of Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg, Germany. gerd.schmitz@klinik.uni-regensburg.de

Studies in Health Technology and Informatics

|April 1, 2008

Summary

This summary is machine-generated.

The Danubian Biobank Consortium integrates biobanking into healthcare for aging research. This initiative creates a central database and regional facilities to advance personalized medicine and support scientific investigations.

More Related Videos

Creation and Maintenance of a Living Biobank - How We Do It

Creation and Maintenance of a Living Biobank - How We Do It

Published on: April 10, 2021

Establishment of a Clinic-based Biorepository

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

Related Experiment Videos

Last Updated: Jul 6, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

Creation and Maintenance of a Living Biobank - How We Do It

Creation and Maintenance of a Living Biobank - How We Do It

Published on: April 10, 2021

Establishment of a Clinic-based Biorepository

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

Area of Science:

Biomedical Research
Biobanking
Personalized Medicine

Background:

Established in 2005, the Danubian Biobank Consortium is a network of universities focused on aging disorders.
The consortium aims to integrate biobanking into healthcare systems via e-health and IT strategies.
Biobanking is crucial for generating long-term patient data and health records.

Purpose of the Study:

To create a central, encrypted patient and sample information database for international research.
To establish local and regional biobanking facilities adhering to Good Practice (GP) and Standard Operating Procedures (SOPs).
To transition healthcare systems towards personalized medicine through integrated biobanking and e-health portals.

Main Methods:

Standardized processing procedures (SPP) for data collection, including patient recruitment and sample handling.
Implementation of a central IT-based databank for encrypted scientific use.
Development of local e-health portals to network healthcare providers, industry, and research institutions in a Public-Private Partnership (PPP) model.

Main Results:

Creation of a common central encrypted patient and sample information database.
Establishment of local and regional biobanking facilities (Regensburg, Vienna, Budapest) for DNA, plasma, and tissue.
Integration of biobanking into healthcare workflows to generate qualified patient databases.

Conclusions:

The consortium facilitates international research interactions and advances personalized healthcare.
E-health portals provide actionable health information for authorized practitioners.
The initiative supports scientific project planning and investigations through secure, encrypted data access.